November 10th 2023
Howard I. Scher, MD, discusses the evolution of molecular testing mechanisms in patients with prostate cancer and highlights the importance of making patient-centered decisions based on test results.
February 8th 2017
Howard I. Scher, MD, chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential that liquid biopsies will have in the treatment landscape of prostate cancer.
November 18th 2016
Howard I. Scher, MD, chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses understanding the genetics of patients with metastatic castration-resistant prostate cancer.
May 13th 2013
Howard I. Scher, MD, from the Memorial Sloan-Kettering Cancer Center, discusses an updated analysis of the COU-AA-302 trial, which examined treatment with abiraterone in men with mCRPC prior to the administration of chemotherapy.
February 15th 2013
Howard I. Scher, MD, from Memorial Sloan-Kettering Cancer Center, discusses the impact of corticosteroids on outcomes for men with metastatic castration-resistant prostate cancer receiving treatment with enzalutamide.
June 30th 2011
Dr. Howard Scher from MSKCC on Using the Circulating Tumor Cells Test
June 28th 2011
Dr. Howard Scher from Memorial Sloan-Kettering on the Future of the Circulating Tumor Cell Test
June 27th 2011
Dr. Howard Scher from Memorial Sloan-Kettering on Circulating Tumor Cells in Prostate Cancer
June 23rd 2011
Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells